Inmune Bio, Inc. (INMB) - Dilution Analysis

10-Q filing | 26.6M shares outstanding

10-K filing | 24.8M shares outstanding

8-K filing: INmune Bio Inc. amended its April 2024 warrants, reducing the exercise price to $1.95 and extending the term to June 30, 2026, in exchange for $0.05 per warrant, resulting in aggregate proceeds of $67,416. ($0.07M proceeds)

10-Q filing | 26.6M shares outstanding

10-Q filing | 26.6M shares outstanding

8-K filing: INmune Bio, Inc. completed a registered direct offering on June 30, 2025, selling 3,000,000 shares of common stock at $6.30 per share, resulting in gross proceeds of approximately $18.9 million. ($18.9M proceeds)

10-Q filing | 22.5M shares outstanding

10-K filing | 22.9M shares outstanding

10-Q filing | 20.2M shares outstanding

S-3/A filing: INMUNE BIO Inc. is offering common stock, preferred stock, warrants, or a combination of these securities, or units, up to a total offering price of $250,000,000.

10-Q filing | 19.3M shares outstanding

10-Q filing | 18.0M shares outstanding

S-3 filing: INMUNE BIO Inc. is filing an S-3 to offer common stock, preferred stock, warrants, or a combination of these securities, or units, up to a total offering price of $250,000,000.

10-K filing | 18.0M shares outstanding

10-Q filing | 18.0M shares outstanding

10-Q filing | 17.9M shares outstanding

8-K filing: CTI Holdings, Inc. terminated its Rule 10b5-1 plan for trading 60,000 shares of the company's common stock on July 26, 2023. The plan was originally established on November 16, 2022.

10-Q filing | 17.9M shares outstanding

10-K filing | 17.9M shares outstanding

10-Q filing | 17.9M shares outstanding

10-Q filing | 17.9M shares outstanding

10-Q filing | 17.9M shares outstanding

8-K filing: INmune Bio, Inc. sold 82,900 shares of its common stock at a price of $8.43 per share for gross proceeds of $698,847. ($0.7M proceeds)

10-K filing | 17.9M shares outstanding

10-Q filing | 17.8M shares outstanding

S-3 filing: This prospectus relates to the public offering of up to 192,533 shares of our common stock by the selling stockholder which is comprised of shares of Common Stock issued to Xencor, Inc.

10-Q filing | 17.7M shares outstanding

8-K filing: INmune Bio, Inc. issued 192,533 shares of common stock to Xencor in exchange for cancellation of an option, and also issued warrants to purchase 45,386 shares of common stock to lenders in connection with a loan agreement. ($3.3M proceeds)

10-Q filing | 14.9M shares outstanding

S-3 filing: This prospectus relates to the public offering of up to 1,693,000 shares of common stock INmune Bio Inc. by the selling stockholder.

S-3 filing: Inmune Bio, Inc. files an S-3 to offer common stock, preferred stock, warrants, or a combination of these securities, or units, for an aggregate initial offering price of up to $250,000,000.

10-K filing | 14.9M shares outstanding

10-Q filing | 13.4M shares outstanding

10-Q filing | 10.8M shares outstanding

10-Q filing | 10.8M shares outstanding

POS AM filing: This prospectus relates to the sale or other disposition from time to time of up to 1,071,000 shares of our common stock by the selling stockholder Lincoln Park Capital Fund, LLC.

S-3 filing: INMUNE BIO, Inc. may offer common stock, preferred stock, warrants, or a combination of these securities, or units, for an aggregate initial offering price of up to $100,000,000.

10-K filing | 10.7M shares outstanding

8-K filing: INmune Bio, Inc. entered into a Repurchase Agreement to purchase 220,000 shares of its common stock from Linda F. Powers at $4.60 per share, for a total purchase price of $1,012,000. ($1.01M proceeds)